Cell Design Labs Sells to Gilead

San Francisco – December 8, 2017 – Cooley advised Cell Design Labs on its sale to Gilead Sciences. The transaction is valued at up to $567 million and includes Gilead’s acquisition of all outstanding shares of Cell Design Labs, including the shares of Cell Design Labs held by Kite Pharma (a subsidiary of Gilead). Partners Ben Beerle and Jamie Leigh led a broad Cooley team advising Cell Design Labs.

“Bringing our robust technology platforms under the Gilead umbrella, with its outstanding research and development capabilities and commitment to innovation, provides an exciting path forward for the development of the next generation of living therapies for patients with cancer,” said Brian Atwood, president and CEO of Cell Design Labs, in a news release.

Cell Design Labs, founded in 2016, is a biotherapeutics company pioneering breakthrough science to develop disruptive cell-based therapies. Based on innovative research from Dr. Wendell Lim’s lab at UC San Francisco, the company leverages the power of the body’s immune system to develop smart living therapies.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. 

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.


Related Contacts
Ben Beerle Partner, San Francisco
Jamie Leigh Partner, San Francisco
Danielle Naftulin Partner, Palo Alto
Rishab Kumar Associate, Palo Alto
Kate Hillier Partner, Palo Alto
Robert L. Jones Partner, Palo Alto
Lisette Sell Special Counsel, San Francisco
Renee Deming Retired Partner, Palo Alto
Mark Windfeld-Hansen Partner, Palo Alto
Stephanie Gentile Partner, New York
Amanda Pacheco Associate, Palo Alto
Jacqueline Grise Partner, Washington, DC
Tanisha A. James Partner, New York
Natasha Leskovsek Partner, Washington, DC
Joshua Mates Partner, San Francisco
Barbara Kosacz Partner, Palo Alto